Published Date : 16 Dec 2022
The global dialysis market size is projected to hit around USD 196.1 billion by 2030, from USD 116.07 billion in 2022 with a noteworthy CAGR of 6.78% from 2022 to 2030.
When the kidneys fail, dialysis helps to maintain electrolyte and fluid balance. Furthermore, the COVID-19 pandemic had a substantial impact on the market. Acute renal infection (AKI) has been proven to be caused by COVID-19 infection, which is largely a respiratory condition. The lockdown also disrupted supply chain operations, affecting the availability of both hemodialysis and peritoneal dialysis, and other vital medical drugs, resulting in a drop in dialysis procedures performed in several dialysis centers.
The COVID-19 pandemic is anticipated to have a large overall market impact as a result of these unfavorable circumstances. Dialysis has a wide range of applications in the treatment of chronic kidney diseases, acute renal injury, those awaiting a kidney transplant, and as a long-term measure when a transplant is not an option. The two categories of dialysis are hemodialysis and peritoneal dialysis. Hemodialysis is the extracorporeal purification of blood, whereas Peritoneal Dialysis is the dialysis of blood using the peritoneum in the patient's abdomen.
Dialysis Market Report Scope
|Market Size In 2022||USD 116.07 Billion|
|Market Size By 2030||USD 196.1 Billion|
|Growth Rate from 2022 to 2030||CAGR of 6.78%|
|Forecast Period||2022 to 2030|
|Segments Covered||By Type, By Dialysis Type, By End User|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America, Middle East and Africa|
Asia-Pacific will account for the majority of total revenue generated in 2020 because of the high incidence of type 2 diabetes and hypertension, the abundance of disposable wealth, and the widespread use of cutting-edge technology. Furthermore, the presence of a large number of dialysis centers in this region, as well as an increase in the number of patients suffering from chronic renal and kidney diseases, are expected to drive market growth. Furthermore, the Asia-Pacific region is expected to have the highest CAGR during the study period, owing to an increase in the incidence rate of kidney failure, low organ transplantation rates, and an increase in healthcare expenditure.
Because of the high prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), North America had a market size of USD 38.87 billion in 2021. Europe is expected to be the second-largest region in terms of market share, with moderate growth over the long term. The region's rapid growth is primarily due to an increasing geriatric population suffering from renal disorders.
The primary factor driving the growth of the dialysis market is the increase in the number of patients with renal illnesses, such as kidney damage brought on by trauma, aging, cancer, or diabetes. The World Health Organization's 2015 Global Burden of Disease study states that a lack of chronic dialysis caused approximately 7.1 million deaths in 2010. The WHO also estimates that 5 million people die each year as a result of renal diseases. As a result, the need for dialysis increases along with the number of people with renal disease.
Aside from physical damage, other factors that contribute to kidney failure include renal malignancy, infection, and autoimmune illnesses including Erdheim-Chester disease and amyloidosis. One of the most frequent reasons of decreased renal function is diabetes, with 422 million people suffering from it in 2014, up from 108 million in 1980, according to the WHO. Renal cancer is another major cause of kidney failure; The World Cancer Research Fund reports that 400,000 new instances of the illness were discovered globally in 2018. The market for dialysis is expanding as a result of the rise in the incidence of these illnesses.
The increasing frequency of end-stage renal illness in both developed and developing nations will increase the demand for dialysis therapy. According to the Government of India, around 220,000 new ESRD patients are added each year. The vast majority of them require dialysis.
Patients suffering from kidney disease or damage all over the world are increasingly interested in kidney transplantation. According to the Global Observatory on Donation and Transplantation, 84,347 kidney transplant procedures were performed worldwide in 2015, representing a 5.60% increase over 2014. This preference for transplantation over dialysis procedures is primarily due to the promise of a better quality of life and a lower risk of death in patients with end-stage kidney disease. Dialysis, on the other hand, requires hours of treatment at a hospital or clinic, with patients reporting low blood pressure, nausea, and abdominal cramps following the procedure. To avoid the inconvenience and pain of dialysis, kidney patients are increasingly opting for a new kidney.
Patients with renal disease are commonly treated at In-Centre Dialysis or at Home Dialysis. One of the key trends in the industry recently has been the increasing preference of patients for receiving care at home, particularly in developed and developing economies. Furthermore, the number of patients opting for treatment in home care settings is expected to rise in the coming years. The COVID-19 outbreak, the worst global pandemic in a century, has had a disproportionate impact on dialysis patients and their healthcare providers. However, the market experienced a surge during the COVID-19 outbreak. As critically ill patients experienced multiple organ failures, including kidney failure, the growing number of patients affected by COVID-19 increased demand for the global dialysis market.
The dialysis market has a huge number of competitors and is quite competitive. The market players include Tier-I enterprises, mid-tier organizations, and startup firms. Businesses are vying for market awareness in an intensely competitive environment. Furthermore, due to the high capital required for manufacturing and marketing products, as well as the time-consuming regulatory approval process, many companies (particularly start-ups and small businesses) struggle to survive and keep up with the industry's growth. This can be a significant barrier for a company to develop long-term innovation capability across all market segments.
October 2019: Fresenius Medical Care North America, a US-based kidney care expert, obtained a 'breakthrough device' designation from the US FDA for its innovative hemodialysis system. The novel gadget, which is still under research and incorporates Endexo, an anti-thrombogenic ingredient, is intended to prevent blood clotting in patients without the need of blood thinners.
May 2020: Medtronic, an Irish medical device company, received De Novo clearance from the US FDA for their system designed to give continuous dialysis to severely sick children. The approval would allow doctors and clinicians to provide young patients with continuous renal replacement therapy (CRRT).
Key Players in the Report
By Dialysis Type
By End User
Buy this Research Report@ https://www.precedenceresearch.com/checkout/1982
You can place an order or ask any questions, please feel free to contact at email@example.com | +1 9197 992 333